Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.035 USD | -1.43% | -4.17% | +30.52% |
Financials (USD)
Sales 2024 * | 44.7M | Sales 2025 * | 39.25M | Capitalization | 268M |
---|---|---|---|---|---|
Net income 2024 * | -139M | Net income 2025 * | -178M | EV / Sales 2024 * | 6 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 6.84 x |
P/E ratio 2024 * |
-11.7
x | P/E ratio 2025 * |
-2.52
x | Employees | 449 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 14.55% |
Latest transcript on Adaptimmune Therapeutics plc
1 day | -2.86% | ||
1 week | -4.55% | ||
Current month | -11.76% | ||
1 month | -2.33% | ||
3 months | -38.60% | ||
6 months | +120.96% | ||
Current year | +32.41% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 57 | 07-12-31 | |
Adrian Rawcliffe
CEO | Chief Executive Officer | 52 | 15-02-28 |
Gavin Wood
DFI | Director of Finance/CFO | 54 | 20-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kristen Hege
BRD | Director/Board Member | 60 | Oct. 31 |
Andrew Allen
BRD | Director/Board Member | 57 | 23-05-31 |
David Mott
CHM | Chairman | 58 | 14-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - | |
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 1.03 | -1.90% | 472 119 |
24-05-24 | 1.05 | +3.96% | 560,532 |
24-05-23 | 1.01 | -3.81% | 800,048 |
24-05-22 | 1.05 | -2.78% | 735,218 |
24-05-21 | 1.08 | -1.82% | 1,314,196 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+32.41% | 268M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.63% | 22.1B | |
-9.14% | 18.34B | |
-41.70% | 16.59B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- ADAP Stock